usgaap-20201118
0000928054False00009280542020-11-182020-11-1800009280542020-10-272020-10-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 18, 2020
Date of Report (Date of earliest event reported)

Flotek Industries, Inc.
(Exact name of registrant as specified in its charter)

Delaware001-1327090-0023731
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
8846 N. Sam Houston Parkway W.,
Houston, TX 77064
(Address of principal executive office and zip code)

(713) 849-9911
(Registrant’s telephone number, including area code)

(Not applicable)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of Exchange on which registered
Common Stock, $0.0001 par valueFTKNYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 7.01    Regulation FD Disclosure.

On November 18, 2020, Flotek Industries, Inc. (the "Company") will participate in the IDEAS Investor Conference. The Company's presentation for the conference is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The presentation slides referenced above contain forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act") and the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such forward-looking statements are subject to risks and uncertainties, as disclosed from time to time in the Company's filings with the Securities and Exchange Commission. As a result of these factors, actual results may differ materially from those indicated or implied by such forward-looking statements.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act.

Item 9.01.    Financial Statements and Exhibits.

    (d)    Exhibits.

Exhibit NumberDescription
99.1





SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FLOTEK INDUSTRIES, INC.
Date: November 18, 2020/s/ Nicholas J. Bigney
Name:Nicholas J. Bigney
Title:Senior Vice President, General Counsel & Corporate Secretary

flotekinvestorpresentati
INVESTOR PRESENTATION November 2020


 
Forward Looking Statements Certain statements set forth in this presentation constitute forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934) regarding Flotek Industries, Inc.’s business, financial condition, results of operations and prospects. Words such as will, continue, expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward- looking statements in this press release. Although forward-looking statements in this presentation reflect the good faith judgment of management, such statements can only be based on facts and factors currently known to management. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Further information about the risks and uncertainties that may impact the Company are set forth in the Company’s most recent filing with the Securities and Exchange Commission on Form 10-K (including, without limitation, in the "Risk Factors" section thereof), and in the Company’s other SEC filings and publicly available documents. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this presentation. 2


 
Meet the New Flotek New management team John W. Gibson, Jr. | Chairman, President & CEO Building entrepreneurial culture with commitment to customer success Michael Borton Ryan Ezell, Ph.D. TengBeng Koid CFO President President Unrelenting focus on delivering shareholder Chemical Technologies Global Business value James Enhanced Board of Directors with focus on governance Nick Bigney James Silas, Ph.D. Danielle Allen SVP, General Counsel & SVP, Research & SVP, Chief of Staff Corporate Secretary Innovation 3


 
Flotek’s Profile SUMMARY METRICS NYSE: FTK Flotek Industries, Inc. is a technology- driven, specialty chemistry and data Market Cap: $193.24 million company that serves customers across industrial, commercial and Cash: $49.9 million consumer markets. Debt: $5.7 million* TTM Revenue: $60.561 million Mission: Apply our knowledge and passion for chemistry to Portfolio of 164 patent assets empower value creation for all of our stakeholders. and growing As of 9/30/2020 *The Company received a $4.8 million loan and JP3 received a $0.9 million loan, both pursuant to the Paycheck Protection Program (PPP) administered by the U.S. Small Business Administration as part of the “CARES” Act.” 4


 
Consumer & Industrial Chemistry as a Common Platform Utilizing same assets, supply chain, logistics, CHEMISTRY R&D to unique buyers Data and markets – flexibility Analytics to deploy to most attractive market Energy opportunities. 5


 
Flotek’s Business Segments Chemistry Technologies Energy Chemistry Sanitizer & Disinfectants Provides specialty chemicals and Delivers high-quality sanitizing and logistics solutions to oil & gas disinfecting products that meet the producers that improve asset demands across a variety of consumer performance and economics. and industrial applications. Data Analytics Flotek’s innovative, real-time data platforms combine the energy industry’s only field-deployable, inline optical analyzer with proprietary cloud visualization and analytics, to optimize processing efficiencies and valuation of natural gas, crude oil and refined fuels. 6


 
Continued Execution against Long-Term Strategic Growth Objectives We have adapted our business while focusing on executing against our strategy. Building a strong foundation for 2021 and beyond. • Reduce dependence on rig count • Expand new product lines that create a greater amount of backlog and/or annual recurring revenue (ARR) • Further differentiate offering from competitors • Enhance capability to provide digital transformation of chemistry • Strengthen market share for our current product lines 7


 
Flotek Operations Global footprint with significant international opportunities across business segments. Flotek Operations Flotek Research 8


 
Chemistry Technologies: Energy Chemistry Transformed business offering unique solution to meet the needs of oil and gas market today and the future Flotek’s energy chemistry business offers a unique 2020: A transformative year for our Energy Chemistry and valuable solution in the marketplace segment • Delivering cost-effective chemistry solutions • Drove down our operational costs • Designing and implementing optimized chemistries • Renegotiated logistics and supplier contracts • Helping operators increase production at lower cost per • Accelerated efficiencies in our business processes barrel produced Focused on reintroducing Flotek to the market and building stronger relationships with our active and successful customers to expand our global GROWTH market share. OPPORTUNITIES International opportunities driving upside, particularly in the Middle East. Recently named NOC chemical partner-of-choice for coiled tubing stimulation. 9


 
Chemistry Technologies: Sanitizer & Disinfectant Business Leverages Flotek’s existing specialty chemistries and diversifies business and revenue stream Q1 2020 Q2 2020 Q3 2020 • Expansion of product line: FDA-and EPA-registered • Launched FDA-quality surface & hand sanitizers for • Began initially as community support initiative. Janitorial & Sanitizing product portfolio industrial and consumer applications. • Flotek produced and donated sanitizers for local • Actively selling FDA-and EPA-registered janitorial • Minimal capital investment to capture long-term, communities in response to the global and sanitizer products into multiple markets. high growth opportunity. pandemic. Customers include: hospitals, hospitality & travel, • Leveraging the same chemistries, facilities, food services, sports & entertainment, e- capabilities as energy chemistries. commerce. • Recently installed packaging line for greater efficiency, lower costs, accelerated order fulfillment. Advance Flotek’s position as a top-selling, high-quality sanitizer and disinfectant manufacturer GROWTH Growth opportunities in the janitorial sanitizer market (JanSan) and contract manufacturing for white label distribution. OPPORTUNITIES Expanded portfolio includes disinfectant wipes and sprays, surface cleaners and degreasers, and manufacturing partnerships with emerging technologies in the JanSan industry. 10


 
PRODUCTS Flotek Chemistry Capability MADE IN THE USA Domestic Blend Facilities 3M+ gal/mo. combined MARLOW, OK WALLER, TX capacity* 90,000 sqft warehouse Full liquid blending and 38,000 sqft warehouse Liquid blending and (heated and ambient bulk storage tanks) QA/QC capabilities (heated and ambient bulk storage tanks) QAQC capabilities ISO Certified FDA 503BcGMP USP 795 Pharmaceutical Compounding of EPA Establishment No: 84892-OK-1 Facilities non-sterile preparations FDA/NDC Labeler Code: 74208 *Manufacturing capacities are on 8 hr shift basis; two shifts are available for liquid/gel Manufacturing capacities are for wipes are approximately 2.0M 80 count canisters/month 11


 
Data Analytics Diversifying Flotek’s Business across all Segments of the Hydrocarbon Value Chain The Need for Real-Time Data in the Modern Age of Oil & Gas Digitalization JP3’s technologies are helping One Technology Platform – Wide Range of Applications Flotek customers accelerate the industry’s digital transformation by providing the real-time data necessary to manage crude oil Upstream Midstream Downstream Distribution Low-cost, real-time analysis of subsurface Gas process plants running Automated Refineries can custom-blend crudes from Refined fuel terminals and pipelines can production flow. Enables evaluation of Process Control systems require real-time multiple day tanks or supply pipelines to be optimized to reduce or eliminate and natural gas processing. crude’s value at the wellhead enables new liquids composition for plant balancing craft optimized feedstock in real time transmix of fuels in common pipelines and contract pricing structures between and give-away reduction instead of running blind significantly increase profits producer and refiner based on actual composition rather than outdated API Gravity proxy • Actively shifting business model to • Leveraging Joint Data Service Solution subscription-based contracts with recurring collaborative agreement with Phillips 66: GROWTH revenue – Optimize transmix. • Gaining positive momentum in international – Targeting refined fuel producers, transporters & OPPORTUNITIES markets, with focus on Middle East, Asia & Africa distribution terminal operations. 12


 
Differentiating Through Research & Innovation Driving innovation in: • Specialty chemical formulations • FDA & EPA regulatory guidance • Data analytics • Basin & reservoir specialization • Technical support & QA/QC 164 • New technology projects and future patent generation products and services assets


 
Renewed Focus on ESG Environmental focus • Patented Complex nano-fluid® chemistry technologies Flotek is strongly committed to excellence in protecting the built upon naturally sustainable and non-toxic citrus oil from orange peels to improve well performance environment, health, safety and security of our employees and productivity. and those who live and work in close proximity to our worksites. • Performance chemistries delivering more efficient acreage development and lower capital intensity. Flotek operations worldwide comply with all local • JP3 technologies provide opportunity to measure requirements and implement additional standards to greenhouse gases and enable customers to achieve and quantify ESG performance goals. protect the environment, health, safety and security of our operations. Safety • TRIR 1.03, exceeds comparable industry safety Our safety, health and environmental goals are designed to statistics. sustain our drive to zero incidents - relentlessly and Community investment responsibly. We constantly emphasize the importance of • Donated thousands of gallons of hand sanitizer to monitoring the safety, security and environmental impact of local communities, including first responders, hospitals, schools, homeless shelters and senior our jobsites. Through our day-to-day due diligence, Flotek residential communities during 1H 2020. strives to be recognized as one of the industry's best performers. 14


 
Third Quarter 2020 Highlights Financials Business Leadership Consolidated revenue was up 43.5% Expanded Flotek’s existing hand sanitizer Appointed Mike Fucci to Flotek’s Board to versus second quarter of 2020, with line to include disinfectants and surface Directors, adding expertise on human improvement from energy chemistry. cleaners and offering a full product capital, diversity & inclusion and business offering for the JanSan Community. transformation to Flotek board. Increased international sales in the UAE by 70% YOY. Rationalized a large portion of inventory and streamlined product portfolio, Lowered expenses notably at JP3 with a reducing SKUs by 35% within the 35% reduction in headcount in addition to Chemistry Technologies segment, decreasing other operating costs. reducing inventory carrying costs by $1.3 million. Healthy balance sheet of $49 million of cash at the end of third quarter with Continued collaborative agreement a low debt level of roughly $5.7 million. between JP3 and Phillips 66. 15


 
Adapting to an Evolving Environment and Well Positioned for the Future Flotek’s differentiated business model is positioned to capture growth on profitability Expanding International Diversifying Portfolio Unlocking Digital Transformation Leveraging Flotek’s international market • Diversification of business through • Digital transformation access, the growth opportunities are large. development of sanitizer and disinfectant business in second quarter 2020. – Through JP3, helping customers • Energy Chemistry Technologies accelerate their digital transformation through real-time composition of – Opportunities in Middle East, Africa & • Acquisition of JP3 acquisition in second valuation data necessary to manage Asia. quarter 2020 provides customer diversification downstream, midstream, crude oil and natural gas processing in – Chemical partner-of-choice for coil and upstream markets. the digital age. tubing stimulation for NOC in Middle East. • Recurring revenue • Data Analytics/JP3 – JP3 is transitioning to a subscription based, SaaS business model, yielding a – Expanding from domestic-only higher margin and a recurring revenue offering to international markets, with stream which mitigates risks in volatile a focus on Middle East, Africa & Asia. commodity markets. 16


 
Investment Highlights Leading developer of Disciplined approach to growth and specialty, performance profitability chemistry – Managing expenses – Inventory rationalization Differentiated portfolio – Pivoting business operations Strong R&D Runway of growth capabilities, world- class research & internationally innovation center Attractive market Empowering digital dynamics transformation Healthy balance sheet


 
Flotek Industries, Inc. Unaudited Condensed Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended Nine Months Ended 9/30/2020 9/30/2019 6/30/2020 9/30/2020 9/30/2019 Recent Financials Revenue $ 12,739 $ 21,879 $ 8,880 $ 41,035 $ 99,827 Costs and expenses: Unaudited Condensed Operating expenses (excluding depreciation and amortization) 29,466 23,622 11,632 63,939 105,711 Corporate general and administrative 2,679 5,685 5,395 12,568 19,020 Consolidated Depreciation and amortization 518 2,058 468 3,177 6,437 Research and development 1,480 2,297 1,638 5,673 6,658 Statement of Operations (Gain) loss on disposal of long-lived assets (37) 3 (22) (92) 1,096 Impairment of goodwill 11,706 - - 11,706 - (in thousands, except share data) Impairment of fixed and long-lived assets 12,521 - - 69,975 - Total costs and expenses 58,333 33,665 19,111 166,946 138,922 Loss from operations (45,594) (11,786) (10,231) (125,911) (39,095) Other (expense) income: Gain on Lease Termination - - 576 576 - Interest expense (19) (1) (16) (40) (2,014) Other income, net 291 436 78 322 1,238 Total other income (expense), net 272 435 638 858 (776) Loss before income taxes (45,322) (11,351) (9,593) (125,053) (39,871) Income tax benefit 81 191 32 6,282 694 Loss from continuing operations (45,241) (11,160) (9,561) (118,771) (39,177) Income from discontinued operations, net of tax - 117 - - 44,583 Net (loss) income (45,241) (11,043) (9,561) (118,771) 5,406 Basic earnings (loss) per common share: Continuing operations $ (0.66) $ (0.19) $ (0.14) $ (1.75) $ (0.67) Discontinued operations, net of tax - - - - 0.76 Basic earnings (loss) per common share $ (0.66) $ (0.19) $ (0.14) $ (1.75) $ 0.09 Diluted earnings (loss) per common share: Continuing operations $ (0.66) $ (0.19) $ (0.14) $ (1.75) $ (0.67) Discontinued operations, net of tax - - - - 0.76 Diluted earnings (loss) per common share $ (0.66) $ (0.19) $ (0.14) $ (1.75) $ 0.09 Weighted average common shares: Weighted average common shares used in computing basic earnings 68,217 58,608 66,035 68,063 58,491 (loss) per common share Weighted average common shares used in computing diluted earnings 68,217 58,608 66,035 68,063 58,491 (loss) per common share (1) Results of the Company’s Consumer and Industrial Chemistry Technologies (“CICT”) segment are presented as discontinued operations for all periods. (2) Prior periods presented for 2019 have been adjusted to reflect revisions to results determined not to be material to those prior periods.


 
v3.20.2
Cover
Nov. 18, 2020
Oct. 27, 2020
Cover [Abstract]    
Document Type 8-K  
Document Period End Date Nov. 18, 2020  
Entity Registrant Name Flotek Industries, Inc.  
Entity Incorporation, State or Country Code DE  
Entity File Number 001-13270  
Entity Tax Identification Number 90-0023731  
Entity Address, Address Line One 8846 N. Sam Houston Parkway W.  
Entity Address, City or Town Houston  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 77064  
City Area Code 713  
Local Phone Number 849-9911  
Soliciting Material false  
Written Communications false  
Pre-commencement Tender Offer false  
Pre-commencement Issuer Tender Offer false  
Title of 12(b) Security Common Stock, $0.0001 par value  
Trading Symbol FTK  
Security Exchange Name NYSE  
Entity Emerging Growth Company false  
Entity Central Index Key   0000928054
Amendment Flag   false